Latest news with #S3VVascularTechnologies
India Gazette
4 days ago
- Health
- India Gazette
Government backs Indian Startup pioneering domestic stroke treatment technology
Mysuru (Karnataka) [India], June 2 (ANI): A breakthrough in India's medical technology landscape has emerged with government backing for S3V Vascular Technologies, a Mysuru-headquartered company developing indigenous stroke intervention devices. The Technology Development Board has greenlit financial assistance for what could become India's first locally-manufactured mechanical thrombectomy system. Addressing a Critical Healthcare Gap Stroke treatment in India faces significant challenges due to expensive imported medical devices. Current thrombectomy procedures--which involve removing blood clots from brain arteries--rely almost entirely on foreign-made equipment, creating cost barriers that prevent many patients from accessing life-saving care. The minimally invasive thrombectomy technique has revolutionised acute stroke treatment, offering superior results compared to traditional clot-dissolving medications when performed promptly. Despite its effectiveness, the procedure remains financially out of reach for numerous Indian patients due to import-dependent pricing. Manufacturing Initiative Takes Shape S3V Vascular Technologies plans to establish comprehensive production capabilities at Tamil Nadu's Medical Devices Park in Oragadam, situated near Sriperumbudur. This facility will create a complete range of specialised neurological intervention instruments, encompassing microcatheters, aspiration systems, precision guidewires, and clot-retrieval stents. Dr. N.G. Vijaya Gopal, the company's founder and managing director, emphasises their commitment to reducing import dependency across the entire supply chain, not merely final assembly. The organisation has already begun pursuing international certifications, including CE marking and FDA approval, targeting export markets spanning Asia, Latin America, Europe, and North America. Strategic Investment Partners The venture has secured support from notable Indian business leaders and investment firms. Larsen & Toubro's Chairman Emeritus A.M. Naik, MK Ventures' Madhusudan Kela, and Rare Enterprises CEO Utpal Sheth have all committed capital to the project. This high-profile investor participation signals growing confidence in India's deep technology and import-substitution healthcare opportunities. Market Potential and Access Challenges India's neurological intervention sector represents approximately $2 billion in market value, yet treatment availability remains concentrated in major urban centres. Rural areas and smaller cities face particular difficulties accessing advanced stroke care due to infrastructure limitations and specialist shortages. S3V aims to bridge this accessibility gap through hospital partnerships focused on simulation-based education programs for emerging neuro-interventionists and radiologists, potentially expanding treatment capacity nationwide. Government Alignment and Innovation Technology Development Board Secretary Rajesh Kumar Pathak highlighted the project's strategic importance, noting its alignment with India's goals to establish the country as a global centre for affordable, sophisticated medical technologies. He emphasised that domestic healthcare innovation represents a crucial component of national health security. The company has developed proprietary intellectual property, including novel clot retriever designs and specialised braid-over-coil aspiration catheter structures. These patented innovations focus on enhancing device safety and effectiveness in challenging clinical situations. Integration with National Health Programs S3V is exploring collaboration opportunities with government healthcare initiatives, particularly integration with Ayushman Bharat and similar national schemes. Successful implementation could dramatically reduce thrombectomy procedure costs while improving patient outcomes across thousands of cases annually. (ANI)
&w=3840&q=100)
Business Standard
6 days ago
- Health
- Business Standard
Centre to aid development of indigenous thrombectomy device for stroke
Technology Development Board to fund S3V Vascular Technologies for manufacturing India's first thrombectomy device, aiming to reduce import dependency and boost stroke care Sanket Koul New Delhi In a push for India's medtech innovation landscape, the Technology Development Board (TDB), under the Centre's Department of Science and Technology (DST), on Friday announced financial support for the development of India's first indigenous thrombectomy device for stroke care. A thrombectomy device is a specialised medical tool used to remove blood clots—also called thrombi—from blood vessels, particularly in the brain, to treat ischaemic strokes. Under the support programme, the TDB will sanction financial assistance to Mysuru-based S3V Vascular Technologies for the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam, in Chennai's Sriperumbudur. Commenting on the development, TDB Secretary Rajesh Kumar Pathak said the project reflects the continued commitment to making India a global hub for affordable, high-end medical technology, especially in areas of critical public health need like stroke care. According to a study recently published in The Lancet Neurology journal, India registered over 1.25 million new stroke cases in 2021, a 51 per cent increase compared to 650,000 cases in 1990. Dr N G Vijaya Gopal, Managing Director of S3V Vascular Technologies, said the company's integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in mechanical thrombectomy but also reduce India's reliance on the import of raw materials required for the manufacturing of these complex, life-saving devices. The company stated that it aims to integrate these devices into government reimbursement programmes such as Ayushman Bharat, thereby unlocking a domestic market estimated at $2 billion. 'As part of its outreach, S3V also plans to collaborate with leading hospitals to offer simulator-based training for young interventionalists—especially in Tier-II cities, where the stroke burden is high,' it said. Gopal added that S3V has initiated the CE and USFDA approval process for these devices to expand access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe, and the United States. The company also intends to file patents for critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and several advanced process technologies.
